Supernus (NASDAQ: SUPN) holders approve directors, say-on-pay and equity plan
Rhea-AI Filing Summary
Supernus Pharmaceuticals, Inc. reported the results of its 2026 annual stockholder meeting, where all four proposals received the required support. Stockholders elected Class I directors Frederick M. Hudson and Charles W. Newhall, III to terms ending at the 2029 annual meeting.
Stockholders approved, on a non-binding basis, the compensation of the company’s named executive officers and ratified KPMG LLP as independent public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares available under the plan. There were 58,039,721 shares of common stock outstanding and entitled to vote as of April 29, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.07, 9.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares entitled to vote: 58,039,721 shares
Votes for Hudson: 45,058,634 votes
Votes for Newhall: 41,743,154 votes
+3 more
6 metrics
Shares entitled to vote
58,039,721 shares
Common stock outstanding and entitled to vote as of April 29, 2026
Votes for Hudson
45,058,634 votes
Election of Class I Director Frederick M. Hudson
Votes for Newhall
41,743,154 votes
Election of Class I Director Charles W. Newhall, III
Say-on-pay support
45,552,633 votes for
Non-binding approval of named executive officer compensation
Auditor ratification support
49,882,228 votes for
Ratification of KPMG LLP for fiscal year ending December 31, 2026
Equity plan amendment support
41,925,692 votes for
Amendment to 2021 Equity Incentive Plan to increase shares
Key Terms
broker non-votes, non-binding basis, independent public accounting firm, 2021 Equity Incentive Plan, +1 more
5 terms
broker non-votes financial
"Name | Votes For | Votes Withheld | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding basis financial
"To approve, on a non-binding basis, the compensation paid to our named executive officers."
independent public accounting firm financial
"Ratification of the appointment of KPMG LLP as the Company’s independent public accounting firm"
An independent public accounting firm is a third-party audit firm that examines a company's financial records and issues a report on whether those statements are accurate and follow accounting rules. Like a neutral inspector or referee, its review gives investors confidence that the numbers can be trusted, reducing the risk of surprises and helping people decide whether the company is financially sound and worth investing in.
2021 Equity Incentive Plan financial
"to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the “Plan”)"
Inline XBRL technical
"Exhibit 104 — The cover page from this on , formatted in Inline XBRL."
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What did Supernus Pharmaceuticals (SUPN) report from its 2026 annual meeting?
Supernus Pharmaceuticals reported that stockholders approved all proposals at the 2026 annual meeting, including director elections, executive compensation, auditor ratification, and an amendment to the 2021 Equity Incentive Plan. The meeting results confirm continued support for management and existing governance structures.
Were Supernus (SUPN) Class I director nominees elected at the 2026 annual meeting?
Yes, both Class I director nominees, Frederick M. Hudson and Charles W. Newhall, III, were elected to serve until the 2029 annual meeting. Hudson received 45,058,634 votes for, while Newhall received 41,743,154 votes for, with broker non-votes recorded for each.
Did Supernus Pharmaceuticals (SUPN) stockholders approve executive compensation on a say-on-pay basis?
Yes, stockholders approved, on a non-binding basis, the compensation of the company’s named executive officers. The advisory vote recorded 45,552,633 votes for, 1,675,355 votes against, 7,714 abstentions, and 3,073,181 broker non-votes, indicating broad support for the existing pay programs.
Which auditor did Supernus (SUPN) stockholders ratify for fiscal year 2026?
Stockholders ratified KPMG LLP as the independent public accounting firm for the fiscal year ending December 31, 2026. The ratification received 49,882,228 votes for, 417,336 votes against, and 9,319 abstentions, with no broker non-votes recorded on this proposal.
What change to the 2021 Equity Incentive Plan did Supernus (SUPN) approve?
Stockholders approved a proposal to amend the 2021 Equity Incentive Plan to increase the number of shares available under the plan. The vote totaled 41,925,692 for, 5,302,088 against, 7,922 abstentions, and 3,073,181 broker non-votes, enabling additional future equity awards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
